Literature DB >> 21175113

Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.

Kevin K Suk1, Audina M Berrocal, Timothy G Murray, Ryan Rich, James C Major, Ditte Hess, Rose A Johnson.   

Abstract

Posterior retinopathy of prematurity (ROP) is unusual in its atypical features and its aggressive, rapidly progressive course. It is more difficult to recognize and to treat, with many of these eyes progressing to retinal detachment despite multiple treatments with laser or cryotherapy. The authors present a case of aggressive posterior ROP refractory to multiple laser treatment. This patient was successfully treated with intravitreal bevacizumab, but required repeat treatment 4 months later. The second injection with bevacizumab was followed by progression to retinal detachment requiring surgery. The patient remains stable after surgery. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175113     DOI: 10.3928/01913913-20101217-06

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  8 in total

1.  Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.

Authors:  B J Lee; J H Kim; H Heo; Y S Yu
Journal:  Eye (Lond)       Date:  2012-06-15       Impact factor: 3.775

Review 2.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

4.  Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.

Authors:  Fen Tang; Michelle E LeBlanc; Weiwen Wang; Dan Liang; Ping Chen; Tsung-Han Chou; Hong Tian; Wei Li
Journal:  Angiogenesis       Date:  2019-01-14       Impact factor: 9.596

5.  Refractive status of Chinese with laser-treated retinopathy of prematurity.

Authors:  Lu Ruan; Hai-Dong Shan; Xing-Zong Liu; Xin Huang
Journal:  Optom Vis Sci       Date:  2015-04       Impact factor: 1.973

Review 6.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

7.  Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.

Authors:  Jeffrey J Tan; Charles L Cai; Eric M Shrier; Lois McNally; Douglas R Lazzaro; Jacob V Aranda; Kay D Beharry
Journal:  J Ophthalmol       Date:  2017-07-09       Impact factor: 1.909

Review 8.  Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.

Authors:  Chang Dai; Keith A Webster; Amit Bhatt; Hong Tian; Guanfang Su; Wei Li
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.